Src as a therapeutic target in men with prostate cancer and bone metastasesSAAD, Fred.BJU international (Papier). 2009, Vol 103, Num 4, pp 434-440, issn 1464-4096, 7 p.Article

The treatment continuum in the management of prostate cancer patients : What's new?SAAD, Fred.European urology. Supplement. 2006, Vol 5, Num 7, pp 539-542, issn 1569-9056, 4 p.Article

Impact of bone metastases on patient's quality of life and importance of treatmentSAAD, Fred.European urology. Supplement. 2006, Vol 5, Num 7, pp 547-550, issn 1569-9056, 4 p.Article

Treatment of bone complications in advanced prostate cancer: Rationale for bisphosphonate use and results of a phase III trial with zoledronic acidSAAD, Fred.Seminars in oncology. 2002, Vol 29, Num 6, pp 19-27, issn 0093-7754, 9 p., SUP21Conference Paper

Zoledronic Acid Improves Clinical Outcomes When Administered Before Onset of Bone Pain in Patients With Prostate CancerSAAD, Fred; EASTHAM, James.Urology (Ridgewood, NJ). 2010, Vol 76, Num 5, pp 1175-1181, issn 0090-4295, 7 p.Article

Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancersSAAD, Fred; LIPTON, Allan.BJU international (Papier). 2005, Vol 96, Num 7, pp 964-969, issn 1464-4096, 6 p.Article

Digital rectal exam following prostatectomy: Is it still necessary with the use of PSA?LATTOUF, Jean-Baptiste; SAAD, Fred.European urology. 2003, Vol 43, Num 4, pp 333-336, issn 0302-2838, 4 p.Article

Bone-directed treatments for prostate cancerSAAD, Fred.Hematology/oncology clinics of North America. 2006, Vol 20, Num 4, issn 0889-8588, x-xi, 947-963 [19 p.]Article

Role of bisphosphonates in prostate cancerSAAD, Fred; SCHULMAN, Claude C.European urology. 2004, Vol 45, Num 1, pp 26-34, issn 0302-2838, 9 p.Article

Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic AcidSAAD, Fred; SEGAL, Scott; EASTHAM, James et al.European urology. 2014, Vol 65, Num 1, pp 146-153, issn 0302-2838, 8 p.Article

Natural history and treatment of bone complications in prostate cancerSAAD, Fred; CLARKE, Noel; COLOMBELC, Marc et al.European urology. 2006, Vol 49, Num 3, pp 429-440, issn 0302-2838, 12 p.Article

Biochemical markers of bone turnover and clinical outcomes in men with prostate cancerSAAD, Fred; EASTHAM, James A; SMITH, Matthew R et al.Urologic oncology. 2012, Vol 30, Num 4, pp 369-378, issn 1078-1439, 10 p.Article

Targeting the receptor activator of nuclear factor-κB (RANK) ligand in prostate cancer bone metastasesSAAD, Fred; MARKUS, Richard; GOESSL, Carsten et al.BJU international (Papier). 2008, Vol 101, Num 9, pp 1071-1075, issn 1464-4096, 5 p.Article

Preserving bone health in patients with hormone―sensitive prostate cancer: the role of bisphosphonatesSAAD, Fred; ABRAHAMSSON, Per-Anders; MILLER, Kurt et al.BJU international (Papier). 2009, Vol 104, Num 11, pp 1573-1579, issn 1464-4096, 7 p.Article

NFκB : un nouveau marqueur kappable de prédire l'évolution du cancer de la prostate = NFκB : a new marker kappable of predicting prostate cancer outcomeLESSARD, Laurent; MES-MASSON, Anne-Marie; SAAD, Fred et al.Bulletin du cancer. 2006, Vol 93, Num 9, pp 891-899, issn 0007-4551, 9 p.Article

The role of bisphosphonates in hormone-refractory prostate cancerSAAD, Fred; KARAKIEWICZ, Pierre; PERROTTE, Paul et al.World journal of urology (Print). 2005, Vol 23, Num 1, pp 14-18, issn 0724-4983, 5 p.Article

Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasisSAAD, Fred; MCKIERNAN, James; EASTHAM, James et al.Urologic oncology. 2006, Vol 24, Num 1, pp 4-12, issn 1078-1439, 9 p.Article

Clinical Benefits and Considerations of Bisphosphonate Treatment in Metastatic Bone DiseaseSAAD, Fred; LIPTON, Allan.Seminars in oncology. 2007, Vol 34, Num 6, issn 0093-7754, S17-S23, SUP4Conference Paper

Randomized, Placebo-Controlled, Phase III Trial of Sunitinib Plus Prednisone Versus Prednisone Alone in Progressive, Metastatic, Castration-Resistant Prostate CancerDROR MICHAELSON, M; OUDARD, Stephane; LAESTADIUS, Fredrik et al.Journal of clinical oncology. 2014, Vol 32, Num 2, pp 76-82, issn 0732-183X, 7 p.Conference Paper

New and Emerging Therapies for Bone Metastases in Genitourinary CancersSAYLOR, Philip J; ARMSTRONG, Andrew J; FIZAZI, Karim et al.European urology. 2013, Vol 63, Num 2, pp 309-320, issn 0302-2838, 12 p.Article

Denosumab and bone-metastasis-free survival in men with @ castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trialSMITH, Matthew R; SAAD, Fred; TAMMELA, Teuvo L et al.Lancet (British edition). 2012, Vol 379, Num 9810, pp 39-46, issn 0140-6736, 8 p.Article

Increased Survival with Enzalutamide in Prostate Cancer after ChemotherapySCHER, Howard I; FIZAZI, Karim; ARMSTRONG, Andrew J et al.The New England journal of medicine. 2012, Vol 367, Num 13, pp 1187-1197, issn 0028-4793, 11 p.Article

Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trialsLIPTON, Allan; FIZAZI, Karim; BILYNSKYY, Boris et al.European journal of cancer (1990). 2012, Vol 48, Num 16, pp 3082-3092, issn 0959-8049, 11 p.Article

Denosumab and Changes in Bone Turnover Markers During Androgen Deprivation Therapy for Prostate CancerSMITH, Matthew R; SAAD, Fred; EGERDIE, Blair et al.Journal of bone and mineral research (Print). 2011, Vol 26, Num 12, pp 2827-2833, issn 0884-0431, 7 p.Article

The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisoneSAAD, Fred; RUETHER, Dean; ERNST, Scott et al.BJU international (Papier). 2008, Vol 102, Num 5, pp 551-555, issn 1464-4096, 5 p.Article